This article is more than 5 years old. Information may no longer be current.
Top stories in hematology/oncology: FDA approves treatments for myelofibrosis, cancers with NTRK gene fusion
Among the top stories in hematology/oncology last week were three actions by the FDA: the approvals of Inrebic for myelofibrosis and Rozlytrek for cancers with neurotrophic tyrosine receptor kinase gene fusion, and the granting of breakthrough therapy designation to Calquence for chronic lymphocytic leukemia.
Other highlights included a study that found antibiotics administered to treat Staphylococcus aureus inhibited disease activity in patients with advanced cutaneous T-cell lymphoma, and research that suggested oral prostate cancer therapies may increase mortality risk for men with cardiovascular conditions.
FDA approves Inrebic for myelofibrosis
The FDA approved fedratinib for the treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis. Read more.
FDA approves Rozlytrek for cancers with NTRK gene fusion, ROS1 -positive non-small cell lung cancer
The FDA granted accelerated approval to entrectinib for the treatment of adults and children with cancers that harbor neurotrophic tyrosine receptor kinase, or NTRK, gene fusion and for whom there are no effective treatments. Read more.
FDA grants breakthrough therapy designation to Calquence for chronic lymphocytic leukemia
The FDA granted breakthrough therapy designation to acalabrutinib as monotherapy for adults with chronic lymphocytic leukemia. Read more.
Antibiotics thwart disease activity in advanced cutaneous T-cell lymphoma
Antibiotics administered to treat Staphylococcus aureus appeared to inhibit disease activity among patients with advanced cutaneous T-cell lymphoma, according to results of a prospective study published in Blood. Read more.
Oral prostate cancer therapies increase mortality risk for men with cardiovascular conditions
Abiraterone acetate and enzalutamide appeared to increase the risk for death among older men with advanced prostate cancer and pre-existing cardiovascular conditions, according to results of a population-based retrospective study published in European Urology. Read more.